에 대한 최신 뉴스 Schrodinger (NASDAQ:SDGR) 주식

Schrodinger

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Inc

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day. 

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th

In a report released today, Steven Mah from TD Cowen maintained a Buy rating on Schrodinger (SDGR – Research Report), with a price target of $42.00...

TD Cowen Sticks to Its Buy Rating for Schrodinger (SDGR)

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

Interest Rate Regimes And ARKG: Underperformance Explained

Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty

Schrodinger (SDGR) announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-N...

Schrodinger presents SGR-3515 preclinical data at ENA 2024

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Schrodinger (SDGR – Research Report). The company's shares clo...

Craig-Hallum Remains a Buy on Schrodinger (SDGR)

ABCL

ABSI

ARKG

BSGM

CDNA

CRSP

EXAI

EXAS

IONS

NTLA

NVDA

PACB

RLAY

RXRX

SDGR

TWST

Press Releases

Schrödinger Reports Strong Second Quarter 2024 Financial Results

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Schrödinger to Present at Jefferies London Healthcare Conference

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

VSee Health

Waystar Holding

BMO Capital

Morgan Stanley

Keybanc

Leerink Partners

Citigroup

Comments

Schrodinger

뉴스

에 대한 최신 뉴스 Schrodinger (NASDAQ:SDGR) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌